C4 Therapeutics Strikes Major Oncology Deal with Merck KGaA
Company Announcements

C4 Therapeutics Strikes Major Oncology Deal with Merck KGaA

The latest announcement is out from C4 Therapeutics (CCCC).

C4 Therapeutics, Inc. has partnered with Merck KGaA in a significant deal to advance cancer treatment, focusing on the development of two targeted protein degraders. The collaboration could yield C4T up to $740 million, plus royalties from sales, while Merck KGaA will cover all costs from development to commercialization. This strategic partnership marks a notable stride in oncology research and offers potential financial windfalls for both companies as they work towards breakthroughs in cancer therapy.

Learn more about CCCC stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyC4 Therapeutics announces first patient dosed in CFT8919 clinical trial
TipRanks Auto-Generated NewsdeskC4 Therapeutics Advances in Protein Degradation Therapy
TheFlyC4 Therapeutics files $400M mixed securities shelf
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App